All KOL Pulse conferences
Post-Conference Intelligence · Dec 6 – Dec 10, 2025

ASH 2025

Orlando, FL — top KOL voices, trial buzz, and themes pulled from verified physician social.
1,004Physician tweets
61Unique KOLs
1.4MTotal impressions
KOL Voices

Who moved the needle at ASH 2025

Top physician voices ranked by impressions. Institutional / media accounts excluded.

Emerging Themes

What KOLs were talking about

Click any theme to see the top tweets that matched.

Samer Al Hadidi, MD,MS,FACP
@hadidisamer
#ASH25 #mmsm @ASH_hematology Treatment Refinement in Multiple Myeloma @SLentzsch Reasons why CAR-T should be positioned before BsAbs https://t.co/cYiU44RR7f
16.0K impressions
Al-Ola A Abdallah MD (USMIRC)
@abdallah81md
🧵 All #ASH25 abstracts for #mmsm in a tweet 10+ Bonus: 1/10: Presentation ID 2387  OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study #mmsm #Myeloma #USMIRC #MedEd
12.1K impressions
Al-Ola A Abdallah MD (USMIRC)
@abdallah81md
Bonus from #ASH25 late abstract: 🧵1/🚨 Breaking from #ASH25! LBA-1 unveils early results from inMMyCAR, the first-in-human Phase 1 study of KLN-1010, a novel in vivo anti-BCMA CAR-T gene therapy for RRMM. #MultipleMyeloma #CellTherapy #mmsm #myeloma
12.1K impressions
Rahul Banerjee, MD, FACP
@rahulbanerjeemd
#ASHkudos to @SLentzsch This is the nicest and most succinct explanation I’ve seen for CAR-T before bsAbs in myeloma 👏 And I agree! Even once MajesTEC-3 approved based on #ASH25 results, please make sure #MMsm pts hear about BCMA CAR-T as an option before starting bsAbs! https://t.co/SdOsA8c0PV
11.1K impressions
Al-Ola A Abdallah MD (USMIRC)
@abdallah81md
Every BCMA CAR-T company has eyes on this talk 👀. The arrival of in vivo CAR-T is an iPhone-moment — and we know how that ended for Nokia and Blackberry. 📉📈 #ASH25 @oncodaily #MedEd #MedTwitter #mmsm @DrPaulyDeSantis @RenoHemonc https://t.co/EizbF2E7y0 https://t.co…
9.6K impressions
Al-Ola A Abdallah MD (USMIRC)
@abdallah81md
1/10 ASH Abstract #ASH2025 #ASHmmsm OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study from 🇨🇳 1/New bispecific CAR-T for multiple myeloma! OL-101 targets both BCMA & GPRC5D using VHH binders to
6.8K impressions
Vincent Rajkumar
@vincentrk
Just in time for #ASH25 MRD in Myeloma: all your questions answered! How to use MRD assessment in practice and research. @ZanwarSaurabh @LeukemiaJnl For a limited time get free access through this link: https://t.co/mrpHowOpNs The principles we discuss apply for all https://t.co/wJ2zxslWbv
6.2K impressions
Toby Eyre
@tobyeyre82
Many congratulations to the GCLLSG for the first read out of #CLL17 No PFS diff between I+V vs I vs VO. Shorter fup but v different to FLAIR results showing a marked PFS adv for MRD-directed I+V vs I. #ASH25 https://t.co/8NSLPaswCY
2.8K impressions
Raj Chakraborty
@rajshekharucms
While single-arm, the 100% MRD-negativity at 10^-6 with short course of Linvosiltemab post-induction is striking! Awaiting the FASTER RCT [Elra vs ASCT] from @CoMMitTrials but hard to imagine Mel-200 will achieve such high MRD-conversion rate based on prior data! #ASH25 https://t.co/qNLTlbfcip
2.2K impressions
Talha Badar
@talhabadarmd
#ASH25 #leusm #ALL #ASHKudo Phase III GIMEMA ALL2820: chemo-free targeted/immunotherapy beats TKI/chemo •Higher CHR + MRD responses, fewer deaths, better EFS/OS •More MRD negativity + fewer relapses vs prior trial •Crossover helps rescue MRD+ patients •Biology-driven https://t.co/HmmMQKVF0…
2.0K impressions
Vincent Rajkumar
@vincentrk
#2 Dual targeting BCMA and CD19 Fastcar-t (GC012F/AZD0120) as first-line therapy for myeloma. Juan Du et al. Novel, next day manufacturing of CART cells! Highly effective 81% sustained (12 month) MRD negative rate. Also dual targeted. #ASH25 Link: https://t.co/STdir458i8
1.8K impressions
Talha Badar
@talhabadarmd
#ASH25 @Anand_88_Patel present data on InO plus dasatinib for Ph+ #ALL 👏👏 Summary: High ≥MR3 rates after 2 cycles of dasatinib + InO VOD seen only in Schema 1; none in Schema 2 Switching to ponatinib boosts depth of response 100% achieved MR4 or NGS-MRD– by Course 3 76% EFS https://t.co/2rjKnNMwDC https://t.co/eIQt…
1.8K impressions
Andres Gomez
@gomezdleonmd
Teclistamab doses can be reduced by half, given for a limited time, and remain highly effective for RR MM patients maximizing access. Look for the TECLISito poster on Sunday at #ASH25 #Shouldvebeenoral #MMsm @rennquevedo @dgomezalmaguer https://t.co/g6Ft1U9RtP
30.9K impressions
NEJM
@nejm
Presented at #ASH25: In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common. Full RedirecTT-1 phase 1b–2 study https://t.co/vNK9Fk0eEJ
24.1K impressions
Al-Ola A Abdallah MD (USMIRC)
@abdallah81md
Finally I found the 10th abstract for #ASH25 🔥🔥🔥 Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of DPd/DVd in Pts with RRMM: majestec-3 1/ 🔥 Practice-changing data in RRMM! MajesTEC-3 is the first phase 3 trial of a BCMA×CD3 bispecific https://t.co/FLt9haCc28
14.7K impressions
NEJM
@nejm
Original Article: Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab (RedirecTT-1 phase 1b–2 study) https://t.co/PFvXEjnh5R #ASH25 | @ASH_hematology https://t.co/DSsgrwAGWX
9.1K impressions
Vincent Rajkumar
@vincentrk
Just out in @NEJM Effective therapy of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal). RedirecTT-1 #ASH25 @myelomaMD @szusmani @mvmateos 80% response rate. 60% PFS at 12 months. https://t.co/fqAPu4pMUc
8.4K impressions
Al-Ola A Abdallah MD (USMIRC)
@abdallah81md
1/10 ASH Abstract #ASH2025 #ASHmmsm OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study from 🇨🇳 1/New bispecific CAR-T for multiple myeloma! OL-101 targets both BCMA & GPRC5D using VHH binders to
6.8K impressions
Al-Ola A Abdallah MD (USMIRC)
@abdallah81md
Abstract 9/10 #ASH25; From the world 🌍 1/🚨 Abstract #abs25-7875 🔥 Updated efficacy & safety data for JNJ-5322, a next-gen BCMA × GPRC5D × CD3 trispecific antibody for relapsed/refractory multiple myeloma (RRMM)! #ASH25 #Myeloma #Immunotherapy #mmsm
8.1K impressions
Talha Badar
@talhabadarmd
#ASH25 Key abstracts to watch in MDS/CMML 👇 ➡️ Deeper insights into Ven+Aza across high-risk and therapy-related #MDS ➡️ Momentum in telomerase inhibitors, TPO agonists & precision-fusion agents ➡️ Emerging immunotherapy strategy for #TP53 mutant disease ➡️ Fascinating https://t.co/UygxS2PN7Q
3.1K impressions
Talha Badar
@talhabadarmd
#ASH25 👇Key abstracts to watch in acute lymphoblastic leukemia #ALL #leusm 🧵 Overall Takeaways — ASH 2025 ALL Landscape Rapid movement toward chemo-free or chemo-lite regimens, especially in Ph+ ALL. TKI + immunotherapy (blina / InO) emerging as new standard-contenders. https://t.co/e0BdxemcPb
2.8K impressions
Ajay Major, MD, MBA
@majorajay
I'm writing for @ASH_hematology #ASHNewsDaily this year! Check out my article previewing #ASH25 Education Program sessions about immunotherapies invading earlier lines of therapy, including interviews with Drs. Doris Hansen, @NicBoissel & @drsarahruth. https://t.co/SdnWVyvfEe https://t.co/Zz2iR…
2.6K impressions
Talha Badar
@talhabadarmd
#ASH25 #leusm #ALL #ASHKudo Phase III GIMEMA ALL2820: chemo-free targeted/immunotherapy beats TKI/chemo •Higher CHR + MRD responses, fewer deaths, better EFS/OS •More MRD negativity + fewer relapses vs prior trial •Crossover helps rescue MRD+ patients •Biology-driven https://t.co/HmmMQKVF0…
2.0K impressions
Rahul Banerjee, MD, FACP
@rahulbanerjeemd
#ASH25 nice work by the US #MMsm Immunotherapy Consortium: CRS doesn’t intrinsically increase the risk of cardiac events after teclistamab bsAb therapy, but prior cardiac history does - co-management with a cardiologist is imperative! https://t.co/ZhX7qZMRKt
1.2K impressions
Top Tweets

The 10 tweets that defined ASH 2025

Physician voices only, ranked by impressions. Click any card to open the original on X.

Vincent Rajkumar
@vincentrk
#1
Unprecedented. #ASH25 Tec-Dara in relapsed myeloma. @mvmateos https://t.co/hjxKrGsmH9
62.6K impressions
Vincent Rajkumar
@vincentrk
#2
This is the one of the most incredible outcome difference I have seen in myeloma: Results of the randomized Majestec-3 trial in myeloma. @mvmateos HR 0.17 !! Late breaker at #ASH25 @ASH_hematology https://t.co/GRCGkQgBjZ
60.1K impressions
Luciano J Costa
@end_myeloma
#3
MajesTEC-3 ASH LBA Best result ever in a RRMM randomized trial. It will transform how we approach myeloma. Congratulations to authors and @JNJNews https://t.co/UhNOesmjXd
58.3K impressions
Vincent Rajkumar
@vincentrk
#4
Just out in the Journal of Clinical Oncology! @JCO_ASCO A paradigm changing paper on MGUS and Smoldering Myeloma @FrancescoMaura4 And it’s Open Access!! https://t.co/XgIW0EyrC9 KEY FINDINGS: 1) We identify for the first time myeloma defining genomic events to differentiate https://t.co/RxkOgtd17y
36.4K impressions
Vincent Rajkumar
@vincentrk
#5
For #ASH25 attendees I’ve been on this platform for 16 years. Here are some tips on how to be productive, and gain influence and credibility on X. 1) Highlight new information, but also give your take on it as well. Thats what makes the content interesting. 2) Be active
35.8K impressions
Andres Gomez
@gomezdleonmd
#6
Teclistamab doses can be reduced by half, given for a limited time, and remain highly effective for RR MM patients maximizing access. Look for the TECLISito poster on Sunday at #ASH25 #Shouldvebeenoral #MMsm @rennquevedo @dgomezalmaguer https://t.co/g6Ft1U9RtP
30.9K impressions
Vincent Rajkumar
@vincentrk
#7
Here are my Top 5 #ASH25 @ASH_hematology myeloma abstracts. #ASH25VR My Top 5 are based on new data, clinical impact, & methodology with links to the full abstract. Bookmark! Thread with countdown 👇
26.7K impressions
Vincent Rajkumar
@vincentrk
#8
OK here it is. Finally. My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD Give comments. I’m willing to adjust it based on your insights. https://t.co/uP8RFXIKYU
20.7K impressions
Vincent Rajkumar
@vincentrk
#9
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia | FDA #ASH25 https://t.co/qSuvlBzklF
18.9K impressions
Vincent Rajkumar
@vincentrk
#10
Just out in @NEJM Majestec-3 trial. Tec-Dara in relapsed myeloma. #ASH25 @End_myeloma @mvmateos Link: https://t.co/DnTeuBMsLU More in thread https://t.co/GrYwRuLUIL
16.1K impressions
← Back to all conferences